Core Insights - BioVie Inc is focusing on addressing the root causes of neurodegeneration, particularly in Parkinson's disease, rather than just treating symptoms [1][4][12] Company Overview - BioVie Inc is a clinical-stage biopharmaceutical company with a market capitalization in the tens of millions [1] - The company is advancing bezisterim (NE3107), an oral small-molecule drug aimed at blocking TNF alpha mediated inflammation and reversing insulin resistance [2] Parkinson's Disease Focus - Parkinson's disease affects approximately one million people in the U.S., with prevalence expected to rise as the population ages [3] - Current treatments, primarily Levodopa, do not slow neurodegeneration and can lead to involuntary movements [3] - BioVie posits that Parkinson's symptoms arise from low dopamine levels and chronic inflammation due to insulin resistance [4] Clinical Trials and Data - BioVie has completed enrollment in the SUNRISE-PD trial, evaluating bezisterim in 60 early-stage Parkinson's patients not yet on levodopa therapy [6] - The trial aims to determine if bezisterim can delay motor decline, differentiating it from existing treatments [6] - Topline data from the SUNRISE-PD trial is expected in April or May 2026, marking a significant catalyst for the company [7] Broader Implications of Bezisterim - Beyond Parkinson's, bezisterim is also being studied for long COVID and Alzheimer's disease, where chronic inflammation plays a role [8] - A 200-patient trial for long COVID is underway, supported by a $13 million non-dilutive grant [8] Additional Clinical Asset - BioVie is also advancing BIV201, targeting ascites associated with late-stage liver disease, with a Phase 2 trial showing over 50% reduction in fluid buildup [9] - The program has received FDA clearance to proceed directly into a Phase 3 study under orphan and fast-track designations [9] Market Position and Investment Outlook - Despite a broad clinical portfolio, BioVie’s valuation remains modest, attributed to market skepticism towards early-stage biotech [10] - The company presents a high-risk, high-reward investment opportunity with multiple catalysts expected in the next 12 to 18 months [11] - 2026 is anticipated to be a significant year for the company, with potential for substantial market impact if clinical data supports its hypotheses [11][12]

Core Viewpoint - Annovis Bio, Inc. has successfully closed a registered direct offering, raising approximately $6 million to support its operations in developing therapies for neurodegenerative diseases like Alzheimer's and Parkinson's disease [1][2]. Group 1: Offering Details - The company offered 4,000,000 shares of common stock at a price of $1.50 per share [1]. - H.C. Wainwright & Co. served as the exclusive placement agent for this offering [2]. - The gross proceeds from the offering were around $6 million, which will be used for working capital and general corporate purposes [2]. Group 2: Regulatory Information - The securities were sold under a "shelf" registration statement on Form S-3, which was filed with the SEC on February 1, 2024, and declared effective on February 12, 2024 [3]. - A prospectus supplement related to the offering was filed with the SEC and is available on their website [3]. Group 3: Company Overview - Annovis Bio is headquartered in Malvern, Pennsylvania, and focuses on innovative therapies for neurodegenerative diseases [5]. - The company aims to improve patient outcomes and quality of life through its research and development efforts [5].

Group 1 - The event will feature an overview from Dr. Sara Kenkare-Mitra, President and Head of Research and Development, focusing on Alector's multistage pipeline and strategies for addressing neurodegeneration [3] - Alector will highlight its progranulin elevating franchise in frontotemporal dementia with GRN mutations (FTD-GRN) and Alzheimer's disease, specifically discussing the development of latozinemab and nivisnebart (formerly AL101) in collaboration with GSK [3]

Table of Contents As filed with the Securities and Exchange Commission on February 1, 2023. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INHIBIKASE THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 26-3407249 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Iden ...